Schisantherin A recovers Aβ-induced neurodegeneration with cognitive decline in mice

Physiology and Behavior

Volumn 132, Issue , 2014, Pages 10-16

  Li, Xiaolong ^a   Zhao, Xu ^a   Xu, Xuan ^a   Mao, Xin ^a   Liu, Zhi ^a   Li, Huan ^a   Guo, Lin ^a   Bi, Kaishun ^a   Jia, Ying ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Cognition enhancing activity; Histopathological changes; Schisantherin A; Successive intracerebroventricular

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; DONEPEZIL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIGNAN; MALONALDEHYDE; SCHISANTHERIN A; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; CYCLOOCTANE DERIVATIVE; PEPTIDE FRAGMENT; SCHIZANDRER A;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HIPPOCAMPUS; HISTOPATHOLOGY; LEARNING DISORDER; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL DETERIORATION; MORRIS WATER MAZE TEST; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHUTTLE BOX TEST; SPATIAL MEMORY TEST; Y-MAZE TEST; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; CHEMICALLY INDUCED; CHEMISTRY; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAZE TEST; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; TOXICITY;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BRAIN; COGNITION DISORDERS; CYCLOOCTANES; DIOXOLES; DISEASE MODELS, ANIMAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INJECTIONS, INTRAVENTRICULAR; LIGNANS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; NEURODEGENERATIVE DISEASES; PEPTIDE FRAGMENTS; SUPEROXIDE DISMUTASE;

EID: 84900808237     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.04.046     Document Type: Article

References (47)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001, 81:741-766.
2. Pratico D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann NY Acad Sci 2008, 1147:70-78.
3. Banks W.A. Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev 2012, 64:629-639.
4. Masters C.L., Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the β-amyloid pathway. Brain 2006, 129:2823-2839.
5. Jay M., Ellis D.O. Cholinesterase inhibitors in the treatment of dementia. JAOA 2005, 3:145-158.
6. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 2008, 29:609-615.
7. Mura T., Dartigues J.F., Berr C. How many dementia cases in France and Europe? Alternative projections and scenarios 2010-2050. Eur J Neurol 2010, 17:252-259.
8. Jellinger K.A., Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 2010, 119:421-433.
9. Chauhan V., Chauhan A. Oxidative stress in Alzheimer's disease. Pathophysiol 2006, 13:195-208.
10. Mattson M.P., Tomaselli K.J., Rydel R.E. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 1993, 621:35-49.
11. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994, 77:817-827.
12. Abe K., Saito H. Amyloid beta neurotoxicity not mediated by the mitogen-activated protein kinase cascade in cultured rat hippocampal and cortical neurons. Neurosci Lett 2000, 292:1-4.
13. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
14. Butterfield D.A. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 2004, 1000:1-7.
15. Shulman R.G., Rothman D.L., Behar K.L., Hyder F. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci 2004, 27:489-495.
16. Poon H.F., Calabrese V., Scapagnini G., Butterfield D.A. Free radicals and brain aging. Clin Geriatr Med 2004, 20:329-359.
17. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 2007, 9:1647-1658.
18. Edward R.W., Andrew R.K., Amir E., Carl W.C. Carbachol increases intracellular free calcium in cultured rat microglia. Brain Res 1993, 3:59-64.
19. Jang J.H., Surh Y.J. β-Amyloid induces oxidative DNA damage and cell death through activation of c-Jun N terminal kinase. Ann NY Acad Sci 2002, 973:228-236.
20. Jeong E.J., Lee H.K., Lee K.Y., Jeon B.J., Kim D.H., Park J.H., et al. The effects of lignan-riched extract of Shisandra chinensis on amyloid-β-induced cognitive impairment and neurotoxicity in the cortex and hippocampus of mouse. J Ethnopharmacol 2013, 146:347-354.
21. Kang S.Y., Lee K.Y., Koo K.A., Yoon J.S., Lim S.W., Kim Y.C., et al. ESP-102, a standardized combined extract of Angelica gigas, Saururus chinensis and Schizandra chinensis, significantly improved scopolamine-induced memory impairment in mice. Life Sci 2005, 76:1691-1705.
22. Hu D., Cao Y., He R., Han N., Liu Z., Miao L., et al. Schizandrin, an antioxidant lignan from Schisandra chinensis, ameliorates Aβ1-42-induced memory impairment in mice. Oxid Med Cell Longev 2012, 2012. (Article ID 721721). 10.1155/2012/721721.
23. Kiso Y., Tohkin M., Hikino H., Ikeya Y., Taguchi H. Schisandra chinensis (Turcz.) Baill. Planta Med 1985, 4:331-334.
24. Guo L.Y., Hung T.M., Bae K.H., Shin E.M., Zhou H.Y., Hong Y.N., et al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol 2008, 591:293-299.
25. McDonald M.P., Dahl E.E., Overmier J.B., Mantyh P., Cleary J. Effects of an exogenous β-amyloid peptide on retention for spatial learning. Behav Neural Biol 1994, 62:60-67.
26. Yamada K., Nitta A., Saito T., Hu J., Nabeshima T. Changes in ciliary neurotrophic factor content in the rat brain after continuous intracerebroventricular infusion of beta-amyloid(1-40) protein. Neurosci Lett 1995, 201:155-158.
27. Paxinos G., Franklin K.B. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
28. Maurice T., Hiramatsu M., Kameyama T., Hasegawa T., Nabeshima T. Cholecystokinin-related peptides, after systemic or central administration, prevent carbon monoxide-induced amnesia in mice. J Pharmacol Exp Ther 1994, 269:665-673.
29. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
30. Ahmad M., Saleem S., Ahmad A.S., Yousuf S., Ansari M.A., Khan M.B., et al. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 2005, 93:94-104.
31. Charlton J.L. Antiviral activity of lignans. J Nat Prod 1998, 61:1447-1451.
32. Cho J.Y., Kim A.R., Park M.H. Lignans from the rhizomes of Coptis japonica differentially act as anti-inflammatory principles. Planta Med 2001, 67:312-316.
33. Kim S.R., Lee M.K., Koo K.A., Kim S.H., Sung S.H., Lee N.G., et al. Dibenzocyclooctadiene lignans from Schisandra chinensis protect primary cultures of rat cortical cells from glutamate-induced toxicity. J Neurosci Res 2004, 76:397-405.
34. Schubert D., Behl C., Lesley R., Brack A., Dargusch R., Sagara Y., et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U.S.A. 1995, 92:1989-1993.
35. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta protein. Ann NY Acad Sci 2000, 924:17-25.
36. Butterfield D.A., Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences in volving amyloid β-peptide-associated free radical oxidative stress. Free Radical Biol Med 2002, 32:1050-1060.
37. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 2000, 267:4912-4916.
38. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988, 263:17205-17208.
39. Freeman B.A., Crapo J.D. Biology of disease: free radicals and tissue injury. Lab Invest 1982, 47:412-426.
40. Slater T.F. Overview of methods used for detecting lipid peroxidation. Methods Enzymol 1984, 105:283-293.
41. Sonkusare S., Srinivasan K., Kaul C., Ramarao P. Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 2005, 77:1-14.
42. Cioanca O., Hritcu L., Mihasan M., Hancianu M. Cognitive-enhancing and antioxidant activities of inhaled coriander volatile oil in amyloid β(1-42) rat model of Alzheimer's disease. Physiol Behav 2013, 120:193-202.
43. Boyd-Kimball D., Castegna A., Sultana R., Poon H.F., Petroze R., Lynn B.C., et al. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005, 1044:206-215.
44. Kim D.H., Kim S., Jeon S.J., Son K.H., Lee S., Yoon B.H., et al. The effects of acute and repeated oroxylin A treatments on Aβ25-35-induced memory impairment in mice. Neuropharmacology 2008, 55:639-647.
45. Akiko S.S., Tomomichi K., Shozo K., Toshio M. Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats. Behav Brain Res 2013, 241:105-111.
46. Ramin M., Azizi P., Motamedi F., Haghparast A., Khodagholi F. Inhibition of JNK phosphorylation reverses memory deficit induced by [beta]-amyloid (1-42) associated with decrease of apoptotic factors. Behav Brain Res 2011, 217:424-431.
47. Wei B.B., Li Q., Fan R.H., Su D., Ou X.L., Chen K.L., et al. UFLC-MS/MS method for simultaneous determination of six lignans of Schisandra chinensis (Turcz.) Baill. in normal and insomniac rats brain microdialysates and homogenate samples: towards an indepth study for its sedative-hypnotic activity. J Pharm Biomed 2013, 77:120-127.